Still in shock from sepsis, biotechnology now has to face healthcare Clinton-style. But research in biotechnology is on the increase as its products surge towards the markets.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Spalding, B. J. Bio/Technology 11, 768–770 (1993).
Burrill, G. S. & Lee, K. B. Biotech 93: Accelerating Commercialization. (Ernst & Young, San Francisco, 1992).
McCormick, D. K. & Goodstein, M. Bio/Technology 11, 994–996 (1993).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McCormick, D., Hodgson, J. A window of opportunity. Nature 365, 676–678 (1993). https://doi.org/10.1038/365676a0
Published:
Issue Date:
DOI: https://doi.org/10.1038/365676a0
This article is cited by
-
Europe at Bio Work: Challenges and Prospects
Nature Biotechnology (1994)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
